Dima Samaha leads Value Strategy and Payer Insights in Certara’s Evidence & Access group. Her recent work has focused on using her health technology assessment (HTA) and Multi-Criteria Decision Analysis (MCDA) expertise to help pharmaceutical and medical device companies navigate the reimbursement landscape, and develop evidence-informed tailor-made strategies and tactics reflecting product value to optimize market access. In prior roles, Dima was an advisor on innovation and external affairs at l’Institut national d’excellence en santé et en services sociaux (INESSS, Québec) where she developed strategies to enhance collaborations among key Québec stakeholders and Canadian and European health technology assessments agencies. At INESSS she created an advisory committee on HTA and innovative technologies that included patients, technology users, government payers, clinicians, researchers, healthcare managers and representatives from the pharmaceutical, biomedical and information technology industries. As an independent consultant, she advised key players in the pharmaceutical and medical devices industries, as well as not-for-profit organizations, on reimbursement pathways, market access strategies, custom monitoring and research activities on the political, legislative and regulatory landscape to assess policy drivers, enablers and challenges to market access. Through her involvement with the World Health Organization, she was involved in key publications on access to medical devices as well as in the development and analysis of the results of its first survey on the status of the use of HTA principles in its 194 Member States.
Dima received her Pharm D from the Lebanese American University. She holds a Master of Advanced Studies in Health Economics and Management from HEC Université de Lausanne.